Veranex Acquires Fusion Biotec
Global, tech-enabled service provider to the MedTech industry Veranex has acquired Fusion Biotec, a design and engineering firm for complex electro-mechanical diagnostic instrumentation and medical devices located in Orange, California.
Fusion boasts a 15,000-square-foot facility in Orange, California, and an in-house team of more than 45 engineering experts, who largely serve medical device and life sciences clients in rapidly developing end-to-end diagnostic instrumentation. The acquisition expands Veranex’s footprint for product design engineering services across the U.S., with combined company offices now in the Eastern, Central, and Western regions, as well as market access and regulatory, quality, and clinical expertise throughout Veranex’s global operations.
“The COVID pandemic has underscored the need for more affordable and reliable rapid diagnostic testing on a massive scale as well as the need for testing closer to the patient,” said Veranex CEO Tom Daulton. “Fusion’s similar methodologies and expertise fits seamlessly into Veranex’s robust Product Design & Engineering solutions group, which has multifaceted capabilities, including diagnostic devices, IVD, and life science development, regulatory, quality and marketing expertise as well as FDA-regulated manufacturing support—all essential for bringing novel diagnostic technology to the market.”
Related Articles
-
The acquisition expands Veranex’s European footprint as well as the scale and scope of its clinical studies capabilities.
-
The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.
-
Hägen, who was a contributor to Medtech Intelligence, spent 28 years building BlackHägen Design to support clients in the development of “mission-critical” products. He was pivotal in the advocacy of human factors and good design practices for medical devices and…
-
Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.
